# Journal Pre-proof

Multicentre International Registry of Open Surgical *Versus* Percutaneous Upper Extremity Access During Endovascular Aortic Procedures

Luca Bertoglio, Gustavo Oderich, Andrea Melloni, Mauro Gargiulo, Tilo Kölbel, Donald J. Adam, Luca Di Marzo, Gabriele Piffaretti, Christopher J. Agrusa, Wouter Van den Eynde, on behalf of the SUPER-AXA Registry Collaborators

PII: S1078-5884(23)00080-1

DOI: https://doi.org/10.1016/j.ejvs.2023.01.046

Reference: YEJVS 8668

To appear in: European Journal of Vascular & Endovascular Surgery

Received Date: 16 June 2022

Revised Date: 8 September 2022

Accepted Date: 27 January 2023

Please cite this article as: Bertoglio L, Oderich G, Melloni A, Gargiulo M, Kölbel T, Adam DJ, Di Marzo L, Piffaretti G, Agrusa CJ, Van den Eynde W, on behalf of the SUPER-AXA Registry Collaborators, Multicentre International Registry of Open Surgical *Versus* Percutaneous Upper Extremity Access During Endovascular Aortic Procedures, *European Journal of Vascular & Endovascular Surgery*, https://doi.org/10.1016/j.ejvs.2023.01.046.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2023 Published by Elsevier B.V. on behalf of European Society for Vascular Surgery.



ourn	D	nra	
oun			

1	<short title="">International Registry of Open Surgical vs. Upper Extremity Access in</short>				
2	Endovascular Aortic Procedures				
3					
4	Multicentre International Registry of Open Surgical Versus Percutaneous Upper				
5	Extremity Access During Endovascular Aortic Procedures				
6					
7	Luca Bertoglio <sup>a, *</sup> , Gustavo Oderich <sup>b</sup> , Andrea Melloni <sup>a</sup> , Mauro Gargiulo <sup>c</sup> , Tilo Kölbel				
8	<sup>d</sup> , Donald J. Adam <sup>e</sup> , Luca Di Marzo <sup>f</sup> , Gabriele Piffaretti <sup>g</sup> , Christopher J. Agrusa <sup>h</sup> and				
9	Wouter Van den Eynde $^{ m i}$ on behalf of the SUPER-AXA Registry Collaborators $^{ m \dagger}$				
10					
11	<sup>a</sup> Division of Vascular Surgery, Vita-Salute San Raffaele University, IRCCS San Raffaele				
12	Scientific Institute, Milan, Italy				
13	<sup>b</sup> Department of Cardiothoracic and Vascular Surgery, The University of Texas Health Science				
14	Centre at Houston, McGovern Medical School, Houston, TX, USA				
15	<sup>c</sup> Vascular Surgery, Department of Experimental, Diagnostic and Speciality Medicine,				
16	University of Bologna, IRCCS S. Orsola Hospital, Bologna, Italy				
17	<sup>d</sup> Department of Vascular Medicine, German Aortic Centre, University Heart and Vascular				
18	Centre, Hamburg, Germany				
19	<sup>e</sup> Department of Vascular Surgery, University Hospitals Birmingham NHS Foundation Trust,				
20	Birmingham, UK				
21	<sup>f</sup> Vascular and Endovascular Surgery Division, Department of Surgery "Paride Stefanini",				
22	Policlinico Umberto I, "Sapienza" University, Rome, Italy				
23	<sup>g</sup> Vascular Surgery and Interventional Radiology, Department of Medicine and Surgery,				
24	University of Insubria School of Medicine, Varese, Italy				
25	<sup>h</sup> Division of Vascular Surgery, New York-Presbyterian Hospital/Weill Cornell Medical				
26	Center, New York, NY, USA				
27	<sup>i</sup> Department of Vascular and Thoracic Surgery, Imelda Hospital, Bonheiden, Belgium				
28					
29	* Corresponding author. Division of Vascular Surgery, Vita-Salute San Raffaele University,				
30	IRCCS San Raffaele Scientific Institute, Via Olgettina, 60, 20132 Milan, Italy.				
31	bertoglio.luca@hsr.it (Luca Bertoglio).				
32					

33 <sup>†</sup> A list of the authors in the collaborative study group is included in Appendix A. 34 35 WHAT THIS PAPER ADDS 36 Data on upper extremity access (UEA) related complications during complex endovascular 37 aortic repair is lacking, with significant variation in reporting standards and no large 38 comparative studies evaluating open surgical and percutaneous access techniques. This study 39 analysed 1 098 patients enrolled in a multicentre international registry, and identified access 40 failure and stroke rates of 6.8% and 3.0%, respectively. There is equivalence in complication 41 rates between the percutaneous and open surgical upper extremity approaches. These data 42 support a more limited use of UEA favouring transfemoral approach with steerable sheaths 43 whenever possible. 44 45 Objective: To investigate access failure (AF) and stroke rates of aortic procedures performed 46 with upper extremity access (UEA), and compare results of open surgical vs. percutaneous 47 UEA techniques with closure devices. 48 **Methods:** A physician initiated, multicentre, ambispective, observational registry 49 (SUPERAXA - NCT04589962) was carried out of patients undergoing aortic procedures 50 requiring UEA, including transcatheter aortic valve replacement, aortic arch, and thoracoabdominal aortic endovascular repair, pararenal parallel grafts, renovisceral and iliac vessels 51 52 repair. Only vascular procedures performed with an open surgical or percutaneous (with a 53 suture mediated vessel closure device) UEA were analysed. Risk factors and endpoints were 54 classified according to the Society for Vascular Surgery and VARC-3 (Valve Academic 55 Research Consortium) reporting standards. A logistic regression model was used to identify 56 AF and stroke risk predictors, and propensity matching was employed to compare the UEA 57 closure techniques. 58 **Results:** Sixteen centres registered 1 098 patients (806 men [73.4%]; median age 74 years, 59 interquartile range 69 – 79 years) undergoing vascular procedures using open surgical (76%) 60 or percutaneous (24%) UEA. Overall AF and stroke rates were 6.8% and 3.0%, respectively. 61 Independent predictors of AF by multivariable analysis included pacemaker ipsilateral to the 62 access (odds ratio [OR] 3.8, 95% confidence interval [CI] 1.2 - 12.1; p = .026), branched/fenestrated procedure (OR 3.4, 95% CI 1.2 - 9.6; p = .019) and introducer internal 63 64 diameter  $\geq$  14 F (OR 6.6, 95% CI 2.1 – 20.7; p = .001). Stroke was associated with female 65 sex (OR 3.4, 95% CI 1.3 – 9.0; p = .013), vessel diameter > 7 mm (OR 3.9, 95% CI 1.1 – 13.8; p = .037), and aortic arch procedure (OR 7.3, 95% CI 1.7 – 31.1; p = .007). After 1:1 66

#### Journal Pre-proof

- 67 propensity matching, there was no difference between open surgical and percutaneous
- 68 cohorts. However, a statistically significantly higher number of endovascular adjunctive
- 69 procedures were recorded in the percutaneous cohort (p < .001).
- 70 Conclusions: AF and stroke rates during complex aortic procedures employing UEA are
- non-negligible. Therefore, selective use of UEA is warranted. Percutaneous access with
- vessel closure devices is associated with similar complication rates, but more adjunctive
- required to avoid surgical exposure.
- 74
- 75 Keywords: Fenestrated/branched endovascular aneurysm repair, Percutaneous, Stroke,
- 76 Thoracic aorta aneurysm, Upper extremity access
- 77

# 78 <H1>INTRODUCTION

Upper extremity access (UEA) is routinely employed in several complex aortic procedures, 79 80 particularly those involving incorporation of renal and splanchnic vessels such as parallel 81 grafts and branched and fenestrated endovascular aortic repairs (B/FEVAR). Instructions for 82 use of off the shelf branched stent grafts for the treatment of thoraco-abdominal aortic 83 aneurysms recommend antegrade deployment of target vessel bridging stents using UEA.<sup>1</sup> 84 Unfortunately, brachial or axillary artery puncture, followed by simple manual compression 85 after sheath removal, is associated with the potential risk of haematoma, pseudoaneurysm, and nerve injury.<sup>2,3</sup> The risk of access failure (AF) with manual compression is higher with 86 larger profile sheaths; therefore, open surgical exposure and repair has been proposed when a 87  $\geq$  7 F sheath is used.<sup>4–6</sup> 88

89 The two major concerns associated with UEA are AF and stroke during aortic arch manipulation.<sup>6,7</sup> While some centres with established protocols for totally percutaneous 90 91 procedures, including UEA, have reported favourable results, a systematic review and meta-92 analysis, including only six series with percutaneous access, demonstrated an increased risk of AF.<sup>5,6,8–10</sup> More recently, several centres have adopted percutaneous UEAs with 93 satisfactory results and low rates of neurological complications or open surgical conversion.<sup>7-</sup> 94 <sup>9,11–13</sup> Nonetheless, the use of a total transfermoral approach has been increasingly used since 95 96 the introduction of steerable sheaths and catheters, to avoid arch manipulations and limit stroke rates.14-16 97

98 The aim of this study was to report the results of a retrospective physician initiated,
99 multicentre international registry designed to investigate AF and stroke rates of UEAs during

- 100 complex endovascular aortic procedures, and to ascertain whether percutaneous access with
- 101 vascular closure devices (VCDs) might have a role in lowering such complications vs. a
- 102 standard open surgical technique.
- 103

### 104 <H1>MATERIALS AND METHODS

### 105 <H2>Registry and Participating Centres

106 The SUPER-AXA (SUrgical Versus PERcutaneous AXillary Artery) International Registry is a physician initiated, international, multicentre, retrospective registry (ClinicalTrials.gov 107 108 identifier: NCT04589962). The study protocol, electronic case report form, and patient 109 consent form were approved by the institutional Ethics Committee of the coordinating centre 110 in October 2020 and complied with the principles of the Declaration of Helsinki. Each participating centre (Table 1) had Institutional Review Board approval, and all patients 111 112 consented for minimal risk retrospective reviews. All centres consented for data sharing 113 agreement, and clinical data were recorded in a deidentified electronic database for 114 subsequent analysis.

115

# 116 <H2>Registry inclusion/exclusion criteria

117 The registry enrolled patients receiving a UEA during cardiac (i.e., transcatheter aortic valve

118 replacement or intra-aortic balloon pump) or endovascular aortic procedures. Surgical

119 accesses were eligible for enrolment regardless of the repair technique employed.

120 Percutaneous accesses were eligible only if a Perclose Proglide VCD (Abbott Vascular, Santa

121 Clara, CA, USA) was primarily employed to close the access. Patients with a previous

- 122 vascular graft (i.e., bypass or patch) at the intended access site were excluded. Indication for
- 123 UEA and access viability were reviewed by the operating physician at the time of the index
- 124 procedure, and no patient was retrospectively excluded according to access vessel anatomy.
- 125 Patients analysed in previously published series were included when they met the

126 abovementioned criteria.<sup>7,8,17,18</sup>

127

### 128 **<H2>***Study design*

- 129 Data from all patients who received a UEA to treat vascular aortic or its side branch
- 130 pathology at the participating centres from 2008 to 2021 were included in the present study
- 131 and subsequently analysed. Previously published cardiac procedures (i.e., transcatheter aortic
- 132 valve replacement) were excluded from the present analysis (Fig. 1).<sup>7</sup>
- 133

### Journal Pre-proof

### 134 <H2>Access technique

Percutaneous and open surgical UEA techniques have been extensively described by registry 135 participants.<sup>5,7,19</sup> Briefly, in the case of standard open surgical access, the intended arterial 136 137 segment was surgically exposed at the beginning or at the end of the endovascular procedure, 138 as a planned strategy. Arteriotomy closure was intended to be primarily achieved by direct 139 running or interrupted sutures. In the case of percutaneous access, the axillary or proximal 140 brachial artery was catheterised under palpation, ultrasound, or angiographic guidance, according to the implanting physician's preference. When a preclose technique was used, one 141 142 or two VCDs (Perclose ProGlide; Abbott Vascular) were deployed according to the intended introducer sheath to be used thereafter. In the case of introducer sheaths smaller than 8 F, one 143 144 VCD might be implanted at the end of the procedure (no preclose). The access status (i.e., haemostasis and limb perfusion) at the end of the procedure was assessed by clinical 145 inspection, ultrasonography, and/or angiography according to the standard participant clinical 146 147 practice.

148

# 149 **<H2>Definitions, reporting standards, and outcome measures**

150 The Society for Vascular Surgery reporting standards were used to describe the pre-operative characteristics and comorbidities.<sup>20,21</sup> The primary endpoints were the AF and stroke rates 151 and predictors, stratified by the UEA technique.<sup>22</sup> AF was defined, according to modified 152 153 VARC-3 (Valve Academic Research Consortium) classification, as the presence of any 154 access site or access related major vascular complication (e.g., vascular perforation, 155 dissection, stenosis, thrombosis, arteriovenous fistula, pseudoaneurysm, or haematoma; or 156 compartment syndrome; or distal non-cerebral embolisation; or unplanned endovascular or 157 surgical intervention; or closure device failure) resulting in death, bleeding, limb or visceral ischaemia, amputation, or irreversible neurological impairment.<sup>22</sup> Stroke was classified as 158 159 any new onset neurological deficit with a positive neuroimaging study, regardless of the 160 severity and the disability score.

Secondary endpoints considered within 30 days included minor access site vascular
complications (haematoma, deep venous thrombosis, arteriovenous fistula, lymphocoele,
infection, pneumothorax, and transient peripheral nerve injury) not requiring adjunctive
invasive procedures, and type and incidence of open surgical and/or endovascular adjunctive
procedures at the access site.

- 166
- 167 **<H2>***Data analysis*

#### Journal Pre-proo

168 Variables were assessed for normality with the Shapiro–Wilk test. Normal continuous variables are expressed as mean  $\pm$  standard deviation, and differences were tested with the 169 170 two-sided t test. Non-normal continuous variables were expressed as median (interquartile 171 range [IQR]), and differences were tested with the Mann–Whitney U test. Categorical 172 variables were expressed as counts and percentages, and the chi-square or Fischer's exact 173 test were used for analysis. Variables with > 50% missing data were excluded from analysis. 174 A logistic regression model was used to identify risk factors for AF and stroke. Data were 175 entered into the model if they had a univariate p value < .10; the UEA technique (surgical vs. 176 percutaneous) was forced into the model to assess its impact and cross-relation with the other predictors. In the multivariable analyses, risk factors for AF were expressed as odds ratios 177 178 (OR) with a 95% confidence interval (CI). To furtherly clarify the impact of the UEA closure 179 technique on AF, a 1:1 propensity score matching was designed with the "nearest neighbor" 180 method on a logistical regression model to identify two comparable subcohorts (surgical vs. percutaneous) in terms of pre-operative variables.<sup>23</sup> Covariates balance was assessed before 181 182 and after matching to confirm the improvement in the balance achieved by matching ("matchit object" function of R-studio "MatchIt" package). Wizard Statistics (version 1.9.38; 183 184 evanmiller.org) and R-Studio (version 1.4.1106; RStudio, Boston, MA, USA) software for 185 macOS were used.

186

### 187 **<H1>RESULTS**

### 188 <H2>Study cohort description

189 The SUPER-AXA registry database included 1 461 patients who had UEA during an aortic 190 procedure. Seventy per cent were male, with a median age of 75 years. Of these, 1 098 191 patients (75.2%) treated at 16 centre underwent a vascular procedure (Fig. 1 and Table 1). 192 These were mostly elective, but 65 patients (5.9%) had emergent/urgent procedures. Overall, 193 open surgical access and repair was used in 833 patients (75.9%) with a 12 F inner diameter 194 (ID) sheath in 746 (67.9%). The preferred access vessels were the axillary artery or the proximal brachial artery at the level of the armpit in 911 patients (83.0%). An interposition 195 196 graft was required in three patients (0.3%). None of the percutaneous accesses was performed at the level of distal brachial or elbow crease.<sup>24</sup> In the percutaneous group (n = 265), 197 198 ultrasound guided puncture was employed in 221 patients (83.4%) using preclosure technique 199 with one VCD in 70 patients (26.4%) or two VCDs in 174 patients (65.7%). Balloon assisted sheath removal was employed in 123 patients (46.4%).<sup>8,25,26</sup> An adjunctive VCD was used in 200

201 32 patients (12.2%). Pre-operative risk factors and procedural details are summarised in
202 Table 2.

203

# 204 <H2>Access related complications

205 Any AF was observed in 75 patients (6.8%). Of these, three experienced permanent nerve 206 injury (0.3%), while temporary nerve injury was recorded in nine (0.8%). Table 3 207 summarises the aetiology, management failure, and its correlation with the type of access 208 employed. No differences in AF were observed between open surgical and percutaneous 209 access closure, but percutaneous access was more frequently associated with bleeding 210 complications (p = .002). The complications of the percutaneous group were more frequently 211 (p < .001) managed with adjunctive endovascular procedures, and six patients (2.3%) 212 required conversion to open exposure and repair to manage the AF. Conversely, the majority 213 (p = .03) of the open surgical access groups were managed with an adjunctive or redo open procedure. Overall, 63 patients (84%) had the AF corrected during their index aortic 214 215 procedure, the remaining in a secondary procedure during the index hospitalisation. With 216 regard to other access complications, arteriovenous fistula was reported in nine patients 217 (0.8%; all open access), wound infection in eight (0.7%), deep venous thrombosis in one 218 (0.1%; percutaneous), and pneumothorax in one (0.1%; percutaneous). Median duration of 219 hospital stay was shorter in the percutaneous group (percutaneous 4 [IQR 3-7] days vs. open 220 7 [IQR 5 – 13] days; p < .001). Table 4 reports the factors associated with AF according to 221 univariable and multivariable analysis: AF was negatively affected by the presence of a 222 pacemaker in the proximity of the access (OR 3.77, 95% CI 1.17 - 12.1; p = .026), 223 F/BEVAR procedure (OR 3.41, 95% CI 1.22 – 9.56; p = .019), and introducer ID  $\ge 14$  F (OR 224 6.57, 95% CI 2.08 - 20.74; p = .001).

225

### 226 <H2>Stroke

227 Ischaemic or haemorrhagic strokes were observed in 33 patients (3.0%), with an incidence of 228 27/894 for B/FEVAR (3.0%), 0/67 for parallel grafts, 1/55 for renovisceral or iliac branch 229 procedures (1.8%), and 5/82 for a ortic arch endovascular repair procedures (6.1%). Table 5 230 summarises the type, region, laterality, and its correlation with the type of access employed. 231 No differences were observed between open surgical and percutaneous access closure with 232 respect to stroke rates, but percutaneous access was more frequently associated with a 233 cerebral (vs. cerebellar) distribution of the lesion (p = .017) and with contralateral (to UEA) 234 location of the lesions (p = .002). The right and left UAE access showed similar stroke

#### Journal Pre-proot

- incidence (4.2% *vs.* 2.4% respectively; p = .11). Table 4 reports the results of the univariable and multivariable analysis of factors associated with stroke: cerebrovascular events were more common in female patients (OR 3.41, 95% CI 1.29 – 9.0; p = .013), UEA vessel diameter > 7 mm (OR 3.87, 95% CI 1.08 – 13.8; p = .037), and after aortic arch procedures
- 239 (OR 7.29, 95% CI 1.71 31.05; *p* = .007).
- 240

# 241 <H2>Surgical versus percutaneous access

- 242 To compare the two endpoints between the two UEA closure techniques groups, and 243 considering the multiple significant differences between the two cohorts highlighted in Table 244 2, a 1:1 propensity matching was performed for the following variables: smoking habit, diabetes, dyslipidaemia, hypertension, chronic obstructive pulmonary disease, female sex, 245 246 anticoagulant and antiplatelet therapy, aortic procedure, and ID of the introducer. After 247 propensity matching (168 vs. 168), the two cohorts proved different only for the following 248 pre-operative and procedural variables: the use of local anaesthesia (p < .001), subclavicular 249 access (p < .001), and left side access (p < .001) were more frequently employed in the 250 percutaneous cohort and elbow crease access (p < .001) in the open surgical arm. The first 251 three factors were differences related to access management, while the access side was not 252 propensity matched because only 37 patients in the percutaneous cohort received right side 253 access. After propensity matching, no significant differences in AF and stroke rate were 254 found between the percutaneous and open surgical access subgroups (Table 6).
- 255

### 256 <H1>DISCUSSION

### 257 <H2>Access related complications

AF after UEA surgical exposure is not uniformly reported in the literature, ranging from 0 to 258 25%, with a rate of peripheral nerve injury ranging from 0 to 9%.<sup>6,27,28</sup> More recently, many 259 260 authors have started to use VCDs to repair percutaneous axillary access in an attempt to 261 lower access related complications, with AF rates ranging from 2 to 18%, but no comparative studies have yet been published.<sup>7,9,29</sup> The present multicentre registry reports an overall AF 262 263 rate of 6.8%, including 0.8% permanent nerve injury, using a uniform definition of failure. In 264 the percutaneous UEA cohort, bleeding rather than occlusive complications occurred more frequently, and were often managed with adjunctive endovascular procedures (i.e., covered 265 266 stenting at the level of vessel puncture). In 2.3% of patients, an open conversion was needed. 267 By contrast, patients receiving primary surgical exposure were more prone to occlusive 268 complications, frequently requiring a patch angioplasty at the level of sheath insertion. The

#### Journal Pre-proo

269 multivariable analysis identified three factors associated with AF (Table 4), and,

270 unsurprisingly, of these, a sheath ID size  $\ge 14$  F (OR 6.6; p = .001) was the strongest

271 predictor. It is quite intuitive that, in UEAs of 8 mm in diameter (Table 2), the use of larger

sheaths might trigger percutaneous VCD failures, as well as dissection flaps that eventually require a surgical correction. A pacemaker at the access site might hamper percutaneous access and VCD placement, while a F/BEVAR procedure might be associated with multiple manipulations of the sheaths, thus increasing the likelihood of vessel damage. Interestingly, even after the inclusion of open/percutaneous UEA management in the multivariable models or after the propensity matching, no significant increase in the AF rates was noted for the percutaneous approach.

279 The real Achilles' heel of UEA remains cerebrovascular complications. The registry 280 results confirmed that the stroke rate of UEA for complex endovascular aortic procedures is 281 not negligible, ranging from 1.8 to 3% of the procedures performed in the thoraco-abdominal 282 region, with no difference observed comparing both the aortic procedure performed (i.e., parallel graft vs. F/BEVAR) and the UEA side employed.<sup>12,19</sup> However, multivariable 283 284 analysis confirmed that an arch procedure (zone 0-2) was associated with higher stroke incidence (OR 7.3; p = .007), in keeping with previous literature findings.<sup>30</sup> Another risk 285 286 factor for stroke was female sex, supporting the evidence of a poorer peri-operative outcome of complex aortic procedures in women.<sup>31,32</sup> Despite no difference in stroke rates between the 287 two UEA closure techniques, stroke was more commonly cerebral (vs. cerebellar) and 288 289 contralateral to the UEA in the patients receiving percutaneous access rather than a surgical 290 one. This finding might suggest that the arch endovascular manipulation of percutaneous 291 access extends more proximally, for example related to the guidewire placement in deploying 292 the VCD, while the manipulation of open surgical access is more limited to the side of the 293 UEA and therefore cerebellar. In the last three years, UEA use decreased in many aortic 294 centres due to the introduction of the transfemoral approach employing homemade or standard steerable sheaths, thereby reducing the incidence of stroke related to the intrinsic 295 arch manipulation when the target vessels are bridged from above.<sup>14,33</sup> Future studies should 296 297 confirm whether avoiding a UEA will significantly lower both the rates of ischaemic and haemorrhagic cerebrovascular complications of complex aortic procedures.<sup>34</sup> 298

This large international registry highlights that percutaneous UEA during vascular procedures is not burdened by higher rates of stroke or AF at both multivariable analysis and propensity matched comparison. The possible clinical advantages of incorporating routine

#### Journal Pre-proo

302 percutaneous UEA require further investigation, but reduced operative time, duration of 303 hospital stay, and blood loss might be beneficial in terms of reduced procedural invasiveness 304 and increased patient quality of life. For example, the present study observed that 305 percutaneous UEA was associated with a shorter hospital stay (p < .001 both in the general 306 and propensity matched groups). Reports of total percutaneous arch branched repair suggest 307 that the applicability of percutaneous techniques to complex endovascular aortic repair will continue to expand,<sup>35,36</sup> and this will have a positive impact on healthcare systems by 308 reducing overall costs.<sup>37</sup> 309

310 Study limitations principally reside in its retrospective nature. It is not possible to 311 report the number of patients in whom a UEA was not considered feasible at the time of 312 procedural planning by the performing physicians and therefore selection bias cannot be 313 excluded. Reporting bias may have affected adverse event rates by under-reporting rates of 314 peripheral nerve injury, for example, which was rarely assessed by an independent neurologist, and cerebrovascular events in asymptomatic patients who were not assessed by 315 316 imaging. Furthermore, the study cohort includes patients in which UEA was used for a wide 317 range of procedures ranging from ascending, arch, and descending aortic repair. Although the 318 larger sample increases the study power, it provides fewer insights on neurological outcomes 319 for each specific vascular intervention. Moreover, certain variables such as blood loss and 320 transfusions have been inconsistently reported, so a dedicated analysis was not possible. 321 Finally, only two of 16 centres employed (and provided data from) both open surgical and 322 percutaneous UEA, while the vast majority appear to favour a single approach.

323

### 324 <H2>Conclusion

325 AF and stroke rates during complex aortic procedures employing UEA are non-negligible; 326 therefore, selective use is warranted. Percutaneous access with vessel closure devices is 327 associated with similar complication rates, but adjunctive endovascular procedures are 328 required to avoid surgical exposure. Registry data appear to refute previous meta-analysis 329 conclusions asserting that a percutaneous UEA is burdened by increased AF vs. surgical exposure.<sup>6</sup> The true clinical implications of the two approaches, as well as the incidence and 330 331 impact of minor complications such as temporary peripheral nerve injury, could be better 332 clarified only by prospective and randomised studies.

333

### 334 CONFLICT OF INTEREST

īυ

- 335 Abbott Vascular, Santa Clara, CA, USA paid IRCCS San Raffaele Hospital a research grant
- for the study (NCT04589962) Principal Investigator Luca Bertoglio is a consultant for Abbott
- 337 Vascular, Santa Clara, CA, USA. The other authors and collaborators have no conflicts of
- interest to declare.
- 339

### 340 FUNDING

- 341 None.
- 342

### 343 ACKNOWLEDGEMENTS

- 344 The paper has been accepted for the forthcoming ESVS 36th Annual Meeting, to be held in
- 345 Rome, as an oral presentation in Prize Fast Track Sessions
- 346

### 347 **REFERENCES**

- 348 1 Bertoglio L, Grandi A, Carta N, Cambiaghi T, Bilman V, Melissano G, et al. Comparison
- of anatomic feasibility of three different multibranched off-the-shelf stent-grafts designed for
   thoracoabdominal aortic aneurysms. *J Vasc Surg* 2021;74:1472–82.
- 2 Alvarez-Tostado JA, Moise MA, Bena JF, Pavkov ML, Greenberg RK, Clair DG, et al. The
- brachial artery: a critical access for endovascular procedures. *J Vasc Surg* 2009;**49**:378–85.
- 353 3 Kiemeneij F, Laarman GJ, Odekerken D, Slagboom T, Van Der Wieken R. A randomized
- 354 comparison of percutaneous transluminal coronary angioplasty by the radial, brachial and
- femoral approaches: the ACCESS study. J Am Coll Cardiol 1997;29:1269–75.
- 4 Kret MR, Dalman RL, Kalish J, Mell M. Arterial cutdown reduces complications after
- brachial access for peripheral vascular intervention. *J Vasc Surg* 2016;**64**:149–54.
- 358 5 Mirza AK, Oderich GS, Sandri GA, Tenorio ER, Davila VJ, Kärkkäinen JM, et al.
- 359 Outcomes of upper extremity access during fenestrated-branched endovascular aortic repair.
- 360 J Vasc Surg 2019;**69**:635–43.
- 361 6 Malgor RD, Marques de Marino P, Verhoeven E, Katsargyris A. A systematic review of
- 362 outcomes of upper extremity access for fenestrated and branched endovascular aortic repair. J
- 363 *Vasc Surg* 2020;**71**:1763–17.
- 364 7 Bertoglio L, Conradi L, Howard DPJ, Kaki A, Van den Eynde W, Rio J, et al. Percutaneous
- 365 transaxillary access for endovascular aortic procedures in the multicenter international PAXA
- 366 registry. J Vasc Surg 2022;75:868–76.
- 367 8 Bertoglio L, Grandi A, Melloni A, Kahlberg A, Melissano G, Chiesa R. Percutaneous
- 368 AXillary Artery (PAXA) access at the first segment during fenestrated and branched

#### Journal Pre-proo

- 369 endovascular aortic procedures. *Eur J Vasc Endovasc Surg* 2020;**59**:929–38.
- 370 9 Agrusa CJ, Connolly PH, Ellozy SH, Schneider DB. Safety and effectiveness of
- 371 percutaneous axillary artery access for complex aortic interventions. Ann Vasc Surg

372 2019;**61**:326–33.

- 373 10 Scott CK, Driessen AL, Gonzalez MS, Malekpour F, Guardiola GG, Baig MS, et al.
- 374 Perioperative neurologic outcomes of right versus left upper extremity access for fenestrated-
- branched endovascular aortic aneurysm repair. *J Vasc Surg* 2022;**75**:794–802.
- 376 11 Yufa A, Mikael A, Gautier G, Yoo J, Vo TD, Tayyarah M, et al. Percutaneous axillary
- 377 artery access for peripheral and complex endovascular interventions: clinical outcomes and
- 378 cost benefits. *Ann Vasc Surg* 2022;**83**:176–83.
- 379 12 Scott CK, Driessen AL, Gonzalez MS, Malekpour F, Guardiola GG, Baig MS, et al.
- 380 Perioperative neurologic outcomes of right versus left upper extremity access for fenestrated-
- 381 branched endovascular aortic aneurysm repair. J Vasc Surg 2022;75:794–802.
- 382 13 Mordhorst A, Yan TD, Hoskins N, Gagnon J, Kazemi K. Percutaneous proximal axillary
- artery versus femoral artery access for endovascular interventions. *J Vasc Surg* 2022;**76**:165–
  73.
- 385 14 Gallitto E, Faggioli G, Bertoglio L, Pratesi G, Isernia G, Goretti M, et al. Steerable sheath
- 386 for cannulation and bridging stenting of challenging target visceral vessels in fenestrated and
- 387 branched endografting. *Ann Vasc Surg* 2020;**67**:26–34.
- 388 15 Kapahnke S, Bürger M, Torsello GF, Omran S, Hinterseher I, Greiner A, et al.
- 389 Cannulation of visceral vessels using a steerable sheath in fenestrated and branched aortic
- 390 endografts. Ann Vasc Surg 2022;85:305–13.
- 391 16 Makaloski V, Tsilimparis N, Rohlffs F, Spanos K, Debus ES, Kölbel T. Use of a steerable
- 392 sheath for retrograde access to antegrade branches in branched stent-graft repair of complex
- aortic aneurysms. *J Endovasc Ther* 2018;**25**:566–70.
- 394 17 Schäfer U, Deuschl F, Schofer N, Frerker C, Schmidt T, Kuck KH, et al. Safety and
- 395 efficacy of the percutaneous transaxillary access for transcatheter aortic valve implantation
- 396 using various transcatheter heart valves in 100 consecutive patients. Int J Cardiol
- 397 2017;**232**:247–54.
- 398 18 Meertens M, Laturnus J, Ling A, Atkinson N, Mees B, Wagner T. Percutaneous Axillary
- 399 artery access in complex endovascular aortic repair. J Vasc Interv Radiol 2019;30:830–5.
- 400 19 Fiorucci B, Kölbel T, Rohlffs F, Heidemann F, Debus SE, Tsilimparis N. Right brachial
- 401 access is safe for branched endovascular aneurysm repair in complex aortic disease. J Vasc
- 402 Surg 2017;**66**:360–6.

- 403 20 Chaikof EL, Fillinger MF, Matsumura JS, Rutherford RB, White GH, Blankensteijn JD, et
- 404 al. Identifying and grading factors that modify the outcome of endovascular aortic aneurysm
- 405 repair. J Vasc Surg 2002;**35**:1061–6.
- 406 21 Fillinger MF, Greenberg RK, McKinsey JF, Chaikof EL. Reporting standards for thoracic
- 407 endovascular aortic repair (TEVAR). *J Vasc Surg* 2010;**52**:1022–33.
- 408 22 Généreux P, Piazza N, Alu MC, Nazif T, Hahn RT, Pibarot P, et al. Valve Academic
- 409 Research Consortium 3: updated endpoint definitions for aortic valve clinical research. J Am
- 410 *Coll Cardiol* 2021;**77**:2717–46.
- 411 23 McMurry TL, Hu Y, Blackstone EH, Kozower BD. Propensity scores: methods,
- 412 considerations, and applications in the Journal of Thoracic and Cardiovascular Surgery. J
- 413 *Thorac Cardiovasc Surg* 2015;**150**:14–19.
- 414 24 Meertens MM, de Haan MW, Schurink GWH, Mees BME. A stopped pilot study of the
- 415 ProGlide closure device after transbrachial endovascular interventions. J Endovasc Ther
- 416 2019;**26**:727–31.
- 417 25 Lee WA, Brown MP, Nelson PR, Huber TS. Total percutaneous access for endovascular
- 418 aortic aneurysm repair ("Preclose" technique). J Vasc Surg 2007;45:1095–101.
- 419 26 Schäfer U, Ho Y, Frerker C, Schewel D, Sanchez-Quintana D, Schofer J, et al. Direct
- 420 percutaneous access technique for transaxillary transcatheter aortic valve implantation: "the
- 421 Hamburg Sankt Georg approach". *J AmColl Cardiol Intv* 2012;**5**:477–86.
- 422 27 Smith DC, Mitchell DA, Peterson GW, Will AD, Mera SS, Smith LL. Medial brachial
- 423 fascial compartment syndrome: anatomic basis of neuropathy after transaxillary
- 424 arteriography. *Radiology* 1989;**173**:149–54.
- 425 28 Tong Z, Gu Y, Guo L, Guo J, Gao X, Li J, et al. An analysis of complications of brachial
- 426 and axillary artery punctures. *Am Surg* 2016;**82**:1250–6.
- 427 29 Branzan D, Steiner S, Haensig M, Scheinert D, Schmidt A. Percutaneous axillary artery
- 428 access for endovascular treatment of complex thoraco-abdominal aortic aneurysms. Eur J
- 429 *Vasc Endovasc Surg* 2019;**58**:344–9.
- 430 30 Charbonneau P, Kölbel T, Rohlffs F, Eilenberg W, Planche O, Bechstein M, et al. Silent
- 431 brain infarction after endovascular arch procedures: preliminary results from the STEP
- 432 registry. *Eur J Vasc Endovasc Surg* 2021;**61**:239–45.
- 433 31 Nana P, Spanos K, Behrendt C, Dakis K, Brotis A, Kouvelos G, et al. Sex specific
- 434 outcomes after complex fenestrated and branched endovascular aortic repair: a systematic
- 435 review and meta-analysis. *Eur J Vasc Endovasc Surg* 2022;64:200–8.
- 436 32 Edman NI, Schanzer A, Crawford A, Oderich GS, Farber MA, Schneider DB, et al. Sex-

- 437 related outcomes after fenestrated-branched endovascular aneurysm repair for
- 438 thoracoabdominal aortic aneurysms in the U.S. Fenestrated and Branched Aortic Research
- 439 Consortium. J Vasc Surg 2021;74:861–70.
- 440 33 Eilenberg W, Kölbel T, Rohlffs F, Oderich G, Eleshra A, Tsilimparis N, et al. Comparison
- 441 of transfemoral versus upper extremity access to antegrade branches in branched
- 442 endovascular aortic repair. *J Vasc Surg* 2021;**73**:1498–503.
- 443 34 Kärkkäinen JM, Cirillo-Penn NC, Sen I, Tenorio ER, Mauermann WJ, Gilkey GD, et al.
- 444 Cerebrospinal fluid drainage complications during first stage and completion fenestrated-
- 445 branched endovascular aortic repair. *J Vasc Surg* 2020;**71**:1109–18.
- 446 35 Settembrini AM, Kölbel T, Rohlffs F, Eleshra A, Debus ES, Panuccio G. Use of a
- 447 steerable sheath for antegrade catheterization of a supra-aortic branch of an inner-branched
- 448 arch endograft via a percutaneous femoral access. *J Endovasc Ther* 2020;**27**:917–21.
- 449 36 Mougin J, Azogui R, Guihaire J, Tyrrell MR, Oderich GS, Fabre D, et al. "First in Man"
- 450 total percutaneous aortic arch repair with 3-inner-branch endografts: a report of two cases.
- 451 Ann Surg 2021;**274**:E652–7.
- 452 37 Uhlmann ME, Walter C, Taher F, Plimon M, Falkensammer J, Assadian A. Successful
- 453 percutaneous access for endovascular aneurysm repair is significantly cheaper than femoral
- 454 cutdown in a prospective randomized trial. J Vasc Surg 2018;68:384–91.
- 455

# 456 FIGURE LEGEND

- 457 **Figure 1.** Study flowchart. UEA = upper extremity access; TAVR = transcatheter aortic
- 458 valve replacement; IABP = intra-aortic balloon pump; LSA = left subclavian artery;
- 459 B/FEVAR = branched/fenestrated endovascular aortic repair; PTA = percutaneous
- 460 transluminal angioplasty; VCD = vascular closure device.
- 461
- 462
- 463
- 464
- 465
- 466
- 467
- 468
- 469
- 470

Table 1. Centres involved in the SUPER-AXA multicentre registry, including enrolment data and					
distribution of percutaneous and surgical	management	of upper extre	mity access.		
Contro	Location	Surgical (n	Percutaneous	Overall ( <i>n</i> =	
Centre		= 833)	( <i>n</i> = 265)	1 098)	
Mayo Clinic	Rochester, MN, USA	344 (41.3)	0	344 (31.3)	
IRCCS San Raffaele	Milan, Italy	78 (9.4)	119 (44.9)	197 (17.9)	
IRCCS S. Orsola	Bologna, Italy	142 (17.0)	0	142 (12.9)	
Heart and Vascular Center	Hamburg, Germany	96 (11.5)	0	96 (8.7)	
University Hospitals NHS Foundation Trust	Birmingha m, UK	80 (9.6)	0	80 (7.3)	
Policlinico Umberto I	Rome, Italy	43 (5.2)	3 (1.1)	46 (4.2)	
Insubria School of Medicine	Varese, Italy	43 (5.2)	0	43 (3.9)	
Weill Cornell Medical Center	New York, USA	0	38 (14.3)	38 (3.5)	
Imelda Hospital	Bonheiden, Belgium	0	35 (13.2)	35 (3.2)	
NHS Foundation Trust	Oxford, UK	0	18 (6.8)	18 (1.6)	
Hospital General Gregorio Marañón	Madrid, Spain	0	15 (5.7)	15 (1.4)	
University of Rome Tor Vergata	Rome, Italy	0	11 (4.2)	11 (1.0)	
Skåne University hospital	Malmo, Sweden	0	10 (3.8)	10 (0.9)	
San Filippo Neri hospital	Rome, Italy	0	9 (3.4)	9 (0.8)	
S. Maria Misericordia Hospital	Perugia, Italy	0	7 (2.6)	7 (0.6)	
University Hospital of Trieste	Trieste, Italy	7 (0.8)	0	7 (0.6)	

471 Data are provided as n (%).

15

# 472

Table 2. Pre-operative and procedural variables of 1 098 patients who received an upper extremityaccess during vascular complex aortic procedures.

Variable	Surgical ( <i>n</i> =	Percutaneous	p	Overall (n =
variable	833)	( <i>n</i> = 265)	value	1 098)
Age – y	74 (69–78)	74 (69–79)	.93	74 (69–79)
Male sex	597 (71.7)	209 (78.9)	.021	806 (73.4)
Body mass index – kg/m <sup>2</sup>	27 (24–30)	27 (24–29)	.69	27 (24–30)
Any smoking habit	556 (66.7)	176 (66.4)	.96	732 (66.7)
Diabetes	72 (8.6)	16 (6.0)	.18	88 (8.0)
Dyslipidaemia	476 (57.1)	138 (52.1)	.18	614 (55.9)
Hypertension	754 (90.5)	203 (76.6)	<.001	957 (87.2)
Chronic obstructive pulmonary disease	264 (31.7)	45 (17.0)	<.001	309 (28.1)
Coronary artery disease	388 (46.6)	111 (41.9)	.19	499 (45.4)
Chronic renal failure	349 (41.9)	105 (39.6)	.74	454 (41.3)
Previous CABG	110 (13.2)	27 (10.2)	.54	137 (12.5)
Previous percutaneous coronary	72 (8 6)	58 (21.9)	< 001	130 (11.8)
intervention	72 (0.0)	50 (21.9)	<.001	150 (11.0)
Society for Vascular Surgery score	8 (5–12)	7 (4–11)	<.001	8 (5–12)
American Society of Anesthesiologists grade	139 (16.7)	81 (30.6)	<.001	220 (20.0)
4	109 (1011)			()
Anticoagulant therapy	130 (15.6)	51 (19.5)	.14	181 (16.5)
Antiplatelet therapy	603 (72.4)	222 (83.8)	<.001	825 (75.1)
Procedure		<u>.</u>		
F/BEVAR TAAA	715 (85.8)	179 (67.5)	<.001	894 (81.4)
Parallel graft TAAA	42 (5.0)	25 (9.4)	.009	67 (6.1)
Peripheral stenting	5 (0.6)	50 (18.9)	<.001	55 (5.0)
Renovisceral procedures	5 (0.6)	29 (10.9)	<.001	34 (3.1)
Iliac procedures	0	21 (7.9)	<.001	21 (1.9)
LSA plug during arch repair	43 (5.2)	3 (1.1)	.004	46 (4.2)
Endovascular arch repair	28 (3.4)	8 (3.0)	.78	36 (3.3)
Fenestrated/branched	10 (1.2)	2 (0.8)	.55	12 (1.1)
Parallel grafts	18 (2.2)	6 (2.3)	.92	24 (2.2)

Local/regional anaesthesia	21 (2.5)	74 (27.9)	<.001	95 (8.7)
Access/puncture site				
Left side	510 (61.2)	228 (86.0)	<.001	738 (67.2)
Subclavicular, proximal axillary	242 (29.1)	170 (64.2)	<.001	412 (37.5)
Armpit, distal axillary/proximal brachial	404 (48.5)	95 (35.8)	<.001	499 (45.4)
Elbow crease, distal brachial	187 (22.4)	0	<.001	187 (17.0)
Diameter at the access site – mm	9 (7–10)	8 (7–9)	.036	8 (7–10)
Surgical scar at the access site	8 (1.0)	4 (1.5)	.67	12 (1.1)
Pacemaker ipsilateral to access	7 (0.8)	18 (6.8)	<.001	25 (2.3)
Left internal mammary artery CABG ipsilateral to access	28 (3.4)	9 (3.4)	.12	37 (3.4)
Dialysis fistula ipsilateral to access	15 (1.8)	1 (0.4)	.11	16 (1.5)
Introducer internal diameter – F	12 (12–12)	12 (8–12)	<.001	12 (10–12)
5-6	18 (2.2)	26 (9.8)	<.001	44 (4.0)
7-8	119 (14.3)	46 (17.4)	.27	165 (15.0)
9–10	61 (7.3)	39 (14.7)	<.001	100 (9.1)
12	612 (73.5)	134 (50.6)	<.001	746 (67.9)
14–16	6 (0.7)	20 (7.5)	<.001	26 (2.4)

473 Unmatched statistical comparison is reported between the surgical and percutaneous access

474 closure cohorts. Data are presented as n (%) or median (interquartile range). CABG =

475 coronary artery bypass graft; F/BEVAR = fenestrated/branched endovascular aneurysm

476 repair; TAAA = thoraco-abdominal aortic aneurysm.

477

# 478

Table 3. Descriptions of surgical and percutaneous upper extremity access in the non-matched cohort of 1 098 patients.

	Surgical	Percutaneous	р	Overall ( <i>n</i> =
	(n = 833)	( <i>n</i> = 265)	value	1 098)
Overall access failure rate	53 (6.4)	22 (8.3)	.28	75 (6.8)
Aetiology				
Bleeding	10 (1.2)	12 (4.5)	.002	22 (2.0)
Pseudoaneurysm	5 (0.6)	3 (1.1)	.41	8 (0.7)
Vessel stenosis/occlusion	7 (0.8)	4 (1.5)	.31	11 (1.0)
Vessel dissection/flap	29 (3.5)	3 (1.1)	.057	32 (2.9)
Permanent nerve injury	2 (0.2)	1 (0.4)	.71	3 (0.3)
Management		3		
Endovascular	5 (0.6)	15 (5.7)	<.001	21 (1.9)
Bare stent	4 (0.5)	3 (1.1)		7 (0.6)
Covered stent	1 (0.1)	12 (4.5)		13 (1.2)
Surgical	46 (5.5)	6 (2.3)	.03	52 (4.7)
Patch repair	29 (3.5)	0		29 (2.6)
Haematoma drainage	9 (1.1)	0		9 (0.8)
Thrombectomy	5 (0.6)	1 (0.4)		6 (0.5)
Direct repair		5 (1.9)		5 (0.5)
Bypass	1 (0.1)	0		1 (0.1)
Other	2 (0.2)	0		2 (0.2)

479 Data are presented as n (%).

480

Table 4. Factors associated with stroke and access failure according to the VARC-3(Valve Academic Research Consortium) reporting standards in the non-matched cohortof 1 098 patients according to univariable and multivariable analysis.

	Access failure							
	Univariab	le analysis		Multivaria	able analysis	5		
Variable	OR	95% CI	p	OR	95% CI	p		
			value			value		
Female sex	2.19	1.35–3.53	.001	2.09	0.93–4.69	.073		
Diabetes	0.30	0.07-1.23	.077	0.75	0.08-6.48	.80		
Previous coronary artery	0.26	0.08–0.85	.017	0.47	0.11–2.22	.34		
bypass graft				$\mathcal{O}$				
Direct anticoagulant	3.00	1.35-6.68	.005	2.31	0.75–7.17	.14		
Pacemaker at the access site	6.16	2.28-	<.001	3.77	1.17–	.026		
		16.69			12.11			
F/BEVAR procedure	3.38	1.35-8.49	.006	3.41	1.22–9.56	.019		
Introducer internal diameter	4.62	2.01-	<.001	6.57	2.08-	.001		
≥14 F	.0	10.59			20.74			
Percutaneous access	1.33	0.07-1.23	.28	2.12	0.91–4.94	.082		
	Stroke	1	1	1	1	1		
Female sex	3.05	1.52–6.12	.001	3.41	1.29–9.00	.013		
Hypertension	4.60	0.76–3.34	.10	0.74	0.09–6.01	.78		
Chronic kidney disease	2.15	1.06-4.37	.030	2.16	0.81–5.75	.12		
SVS score ≥10	1.78	0.89–3.57	.098	1.56	0.55-4.46	.40		
Access vessel diameter >7	7.52	2.53-	.038	3.87	1.08–	.037		
mm		22.32			13.83			
Scar at the access site	6.12	1.26–	.011	2.37	0.36–	.37		
		29.71			15.72			
Aortic arch procedure	4.45	1.48–	.004	7.29	1.71–	.007		
		13.42			31.05			
Introducer internal diameter	4.62	1.31–	.009	1.41	0.27–7.36	.69		
≥14 F		16.26						
Access failure	3.95	1.65–9.42	<.001	2.21	0.60-8.17	.23		

Percutaneous access	1.60	0.76–3.34	.21	1.90	0.68–5.27	.22
---------------------	------	-----------	-----	------	-----------	-----

 $482 \qquad OR = odds \ ratio; \ CI = confidence \ interval; \ F/BEVAR = fenestrated/branched \ endovascular$ 

484

building

485

¥7	Surgical ( <i>n</i> =	Percutaneous	p	Overall (n =
variable	833)	( <i>n</i> = 265)	value	1 098)
Overall stroke rate	22 (2.6)	11 (4.2)	.21	33 (3.0)
Туре				<u> </u>
Ischaemic	13 (65)	6 (54)	.57	19 (61)
Haemorrhagic	7 (35)	5 (45)	.57	12 (39)
Missing	2	-	_	2
Region				
Cerebral/anterior	10 (53)	9 (82)	.017	19 (63)
Cerebellar/posterior	6 (32)	1 (9)	.16	7 (23)
Both	3 (16)	1 (9)	.60	4 (13)
Missing	3	_	_	3
Side				
Ipsilateral to UEA	10 (53)	3 (27)	.18	13 (43)
Contralateral to UEA	2 (10)	7 (64)	.002	9 (30)
Bilateral	7 (37)	1 (9)	.098	8 (27)
Missing	3	-	_	3

486 Data are presented as n (%).

487

Table 6. Pre-operative and procedural patient and access characteristics, intra-operative details, and primary outcomes in the matched patient cohorts according to upper extremity access closure modality.

Variable	Surgical ( <i>n</i> =	Percutaneous	p	Overall (n =	
	168)	( <i>n</i> = 168)	value	336)	
Age – y	74 (68–78)	78 (70–87)	.74	74 (68–78)	
Male sex	129 (76.8)	136 (81.0)	.35	265 (78.9)	
Body mass index $- kg/m^2$	26 (23–30)	26 (24–29)	.93	26 (24–29)	
Any smoking habit	113 (67.3)	111 (66.1)	.88	224 (66.7)	
Diabetes	8 (4.8)	7 (4.2)	.80	15 (4.5)	
Dyslipidaemia	97 (57.7)	86 (51.2)	.25	183 (54.5)	
Hypertension	138 (82.1)	138 (82.1)	.91	276 (82.1)	
Chronic obstructive pulmonary disease	42 (25.0)	37 (22.0)	.60	79 (23.5)	
Coronary artery disease	83 (49.4)	72 (42.9)	.25	155 (46.1)	
Chronic renal failure	78 (46.4)	71 (42.3)	.72	150 (44.3)	
Previous CABG	28 (16.7)	19 (11.3)	.34	47 (14.0)	
Previous percutaneous coronary intervention	22 (13.1)	35 (20.8)	.25	57 (17.0)	
Society for Vascular Surgery score	8 (5–12)	7 (4–12)	.71	8 (5–12)	
American Society of Anesthesiologists score 4	34 (20.2)	44 (26.2)	.20	78 (23.2)	
Anticoagulant therapy	24 (14.3)	22 (13.1)	.77	46 (13.7)	
Antiplatelet therapy	141 (83.9)	142 (84.5)	.88	283 (84.2)	
Procedure		I	1		
F/BEVAR TAAA	137 (81.5)	134 (79.8)	.68	271 (80.7)	
Parallel graft TAAA	21 (12.5)	20 (11.9)	.87	41 (12.2)	
Peripheral stenting	5 (3.0)	6 (3.6)	.76	11 (3.3)	
Left subclavian artery plug during arch	0	3 (1.8)	.082	3 (0.9)	
F/BEVAR or parallel arch	5 (3.0)	5 (3.0)	1.0	10 (3.0)	
Local/regional anaesthesia	10 (6.0)	46 (27.4)	<.001	56 (16.7)	
Access/puncture site		1	1	1	
Left side	103 (61.3)	144 (85.7)	<.001	247 (73.5)	
Subclavicular, proximal axillary	65 (38.7)	110 (65.5)	<.001	175 (52.1)	

\_\_\_

Armpit, distal axillary/proximal	59 (35.1)	58 (34.5)	.91	117 (34.8)
brachial				
Elbow crease, distal brachial	44 (26.2)	0	<.001	44 (13.1)
Diameter at the access site – mm	8 (6–10)	9 (7–9)	.34	8 (7–10)
Surgical scar at the access site	3 (1.8)	2 (1.2)	.65	5 (1.5)
Pacemaker ipsilateral to access	3 (1.8)	9 (5.4)	.40	12 (3.6)
Left internal mammary artery CABG	7 (4.2)	4 (2.4)	.095	11 (3.3)
ipsilateral to access				
Dialysis fistula ipsilateral to access	4 (2.4)	1 (0.6)	.19	5 (1.5)
Introducer internal diameter – F	12 (10–12)	12 (10–12)	.45	12 (10–12)
5–6	7 (4.2)	8 (4.8)	.79	15 (4.5)
7–8	23 (13.7)	29 (17.3)	.36	52 (15.5)
9–10	19 (11.3)	20 (11.9)	.86	39 (11.6)
12	114 (67.9)	107 (63.7)	.42	221 (65.8)
14–16	4 (2.4)	4 (2.4)	1.0	8 (2.4)
UEA access failure	10 (6.0)	12 (7.1)	.66	22 (6.5)
Stroke	6 (3.6)	6 (3.6)	1.0	12 (3.6)

488 Data are presented as n (%) or median (interquartile range). CABG = coronary artery bypass

489 graft; F/BEVAR = fenestrated/branched endovascular aneurysm repair; TAAA= thoraco-

490 abdominal aortic aneurysm.

491

### **APPENDIX A**

### **SUPER-AXA Registry Collaborators**

Dominic PJ Howard <sup>j</sup>, Javier Rio <sup>k</sup>, Stefano Fazzini <sup>1</sup>, Nuno V. Dias <sup>m</sup>, Sonia Ronchey <sup>n</sup>, Gianbattista Parlani<sup>o</sup>, Mario D'Oria <sup>p</sup>, Emanuel R. Tenorio <sup>b</sup>, Enrico Gallitto <sup>c</sup>, Giuseppe Panuccio <sup>d</sup>, Martin Claridge <sup>e</sup>, Wassim Mansour <sup>f</sup>, Federico Fontana <sup>g</sup>, Rosa Aurora Chu <sup>h</sup>, Jürgen Verbist <sup>i</sup>, Inga U. Builyte <sup>j</sup>, Jose M. Ligero <sup>k</sup>, Arnaldo Ippoliti <sup>1</sup>, Björn Sonesson <sup>m</sup>, Maria Lucia Locca <sup>n</sup>, Massimo Lenti <sup>o</sup>, Sandro Lepidi <sup>p</sup> and Roberto Chiesa <sup>a</sup>

<sup>a</sup> Division of Vascular Surgery, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Milan, Italy

<sup>b</sup> Department of Cardiothoracic and Vascular Surgery, The University of Texas Health Science Centre at Houston, McGovern Medical School, Houston, TX, USA

<sup>c</sup> Vascular Surgery, Department of Experimental, Diagnostic and Speciality Medicine, University of Bologna, IRCCS S. Orsola Hospital, Bologna, Italy

<sup>d</sup> Department of Vascular Medicine, German Aortic Centre, University Heart and Vascular Centre, Hamburg, Germany

<sup>e</sup> Department of Vascular Surgery, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK

<sup>f</sup> Vascular and Endovascular Surgery Division, Department of Surgery "Paride Stefanini", Policlinico Umberto I, 'Sapienza' University, Rome, Italy

<sup>g</sup> Vascular Surgery and Interventional Radiology, Department of Medicine and Surgery, University of Insubria School of Medicine, Varese, Italy

<sup>h</sup> Division of Vascular Surgery, New York-Presbyterian Hospital/Weill Cornell Medical Center, New York, NY, USA

<sup>i</sup> Department of Vascular and Thoracic Surgery, Imelda Hospital, Bonheiden, Belgium

<sup>j</sup> Department of Vascular Surgery, Oxford University Hospitals NHS Trust, Oxford, UK

<sup>k</sup> Servicio de Angiología y Cirugía Vascular, Hospital General Universitario Gregorio Marañón, Madrid, Spain.

<sup>1</sup> Vascular Surgery Unit, Biomedicine and Prevention Department, University of Rome Tor Vergata, Rome, Italy

<sup>m</sup> Department of Thoracic Surgery and Vascular Diseases, Vascular Centre, Skåne University Hospital, Malmö, Sweden <sup>n</sup> Department of Vascular Surgery, San Filippo Neri Hospital, Rome, Italy

<sup>o</sup> Vascular and Endovascular Surgery Unit, S. Maria Misericordia Hospital, University of Perugia, Perugia, Italy

<sup>p</sup> Division of Vascular Surgery, Cardiovascular Department, University Hospital of Trieste ASUGI, Trieste, Italy

Journal Prevention

Journal Pre-proof



# Short title:

International Registry of Open Surgical vs. Upper Extremity Access in Endovascular Aortic Procedures

# Appendix A:

Appendix A is provided with the full list of collaborators

# **Supplementary material:**

None

# **Figures:**

Figure 1 is a flowchart. Follow the instructions on page C1 for the correct layout and design. Please also make the following changes:

- Insert a thin space in 1 461 and 1 098.
- All 'n' should be in italics and there should be a thin space on either side of all '=' symbols.